Dr. Buckstein's research is clinical and focused on novel biological therapies for MDS and lymphomas. She is a clinician-investigator and interacts closely with the scientists of Sunnybrook Research Institute and elsewhere on collaborative projects. She conducts investigator-initiated research in the following areas:
targeted therapy and immunotherapy
red blood cell transfusions in MDS
MDS mutations as a component of aging
health outcomes research
patient reported outcomes
frailty and comorbidity as prognostic factors.
Dr. Buckstein is supported by research funding from the Canadian Institutes of Health Research and Canadian Cancer Society Research Institute.